Showing results (11-20 of 124) with videos related to
Sort By:
Pageof 13
Stroke|September 2, 1999
Evaluation of genetic risk factors for silent brain infarctionY Notsu, T Nabika, H Y Park, et al.Proceedings of the National Academy of Sciences of the United States of America|August 1, 1984
Phosphorylation at a tyrosine residue of lipomodulin in mitogen-stimulated murine thymocytesF Hirata, K Matsuda, Y Notsu, et al.Clinical and Experimental Pharmacology & Physiology|May 4, 1999
Effects of apolipoprotein A gene polymorphisms on lipoprotein (a) concentrations in JapaneseH Y Park, T Nabika, Y Notsu, et al.Japanese Journal of Pharmacology|December 29, 2000
Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinedionesA Suzuki, T Yasuno, H Kojo, et al.Life Sciences|January 1, 1993
An endothelin ETA receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogsH Nirei, K Hamada, M Shoubo, et al.Molecular Pharmacology|September 1, 1995
Novel steroid 5 alpha-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genesH Kojo, O Nakayama, J Hirosumi, et al.Agents and Actions|January 1, 1986
Isolation and characterization of lipocortin (lipomodulin)F Hirata, Y Notsu, R Yamada, et al.Rinsho Byori. the Japanese Journal of Clinical Pathology|August 1, 1994
[The appropriateness of using the essential laboratory tests in a daily primary medical care]J EndoThe Prostate|June 1, 1997
FR146687, a novel steroid 5 alpha-reductase inhibitor: in vitro and in vivo effects on prostatesO Nakayama, J Hirosumi, N Chida, et al.The Journal of Pharmacology and Experimental Therapeutics|March 1, 1993
Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonistK Sogabe, H Nirei, M Shoubo, et al.Pageof 13